What's Happening?
A post-hoc analysis of the AFIRE trial has revealed that rivaroxaban monotherapy is particularly beneficial for patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) who have low systolic blood pressure (SBP). The study found
that low SBP is associated with a higher risk of adverse cardiovascular events. Rivaroxaban monotherapy showed favorable outcomes in terms of efficacy and safety, especially in patients with low SBP, compared to combination therapy. This suggests that monotherapy could be a viable strategy to balance ischemic and bleeding risks in this patient group.
Why It's Important?
The findings from the AFIRE trial analysis are significant for the management of patients with AF and stable CAD, particularly those with low SBP. The study supports the use of rivaroxaban monotherapy as a safer and more effective treatment option, potentially reducing the risk of both ischemic and bleeding events. This could influence clinical guidelines and treatment strategies, offering a tailored approach for patients with specific cardiovascular profiles. The results also highlight the importance of considering SBP levels in treatment decisions to improve patient outcomes.
